Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Intralipid 10%
- Development stage
- Approved
- Lead developer
- Fresenius Kabi
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**Intralipid 10%** is a sterile intravenous soybean-oil lipid emulsion used in parenteral nutrition to provide calories and essential fatty acids, including linoleic acid and alpha-linolenic acid. It contains 10% soybean oil, egg-yolk phospholipids as an emulsifier, glycerin, water for injection, and sodium hydroxide for pH adjustment. Infused lipid particles are metabolized similarly to chylomicrons, supplying energy and preventing or correcting essential fatty acid deficiency in patients unable to obtain adequate nutrition enterally. The product originated from work led by Arvid Wretlind and collaborators in Sweden and has been marketed by Fresenius Kabi.
- Brand names
- Intralipid 10%
- Other names
- Intralipid 10% w/vIntralipid-10%
02
Targets
PPARA (Peroxisome proliferator-activated receptor alpha)NaV alpha (Voltage-gated sodium channel alpha subunit family)
Beyond the preview
Go deeper on Intralipid 10%.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Intralipid 10%.